Nestor 2022 - ALT-801 GLP-1/Glucagon Dual Agonist in NASH Models

Communications Biology·April 1, 2022

J. J. Nestor

Summary

ALT-801 showed reductions in liver fat, body weight, and metabolic disease markers in preclinical NASH models, supporting clinical development of pemvidutide.

Study Details

Study Design

Preclinical NASH and metabolic disease study

Indication

NASH / metabolic dysfunction-associated liver disease

Intervention

ALT-801 / pemvidutide

Species

Animal

Risk of Bias Assessment

Preclinical study